AbbVie (ABBV) Shares are Down -3.71%

AbbVie (ABBV) : During the past 4 weeks, traders have been relatively bearish on AbbVie (ABBV), hence the stock is down -2.24% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.07% relative to the S&P 500. The 4-week change in the price of the stock is -2.45% and the stock has fallen -3.71% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 2.89% and the fifty day Moving Average is 0.97%. AbbVie Inc. is up 3.93% in the last three month period. Year-to-Date the stock performance stands at 12.25%.

AbbVie (ABBV) : 12 Wall Street analysts covering AbbVie (ABBV) believe that the average level the stock could reach for the short term is $71.75. The maximum price target given is $90 and the minimum target for short term is around $47, hence the standard deviation is calculated at $11.15.


AbbVie (NYSE:ABBV): On Fridays trading session , Opening price of the stock was $64.68 with an intraday high of $65.02. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $64.21. However, the stock managed to close at $64.61, a loss of 0.17% for the day. On the previous day, the stock had closed at $64.72. The total traded volume of the day was 7,041,630 shares.

AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.